FDA Approves Pain Reliever Tapentadol
Health care professionals have an additional choice for treating patients with moderate to severe acute pain. The U.S. Food and Drug Administration (FDA) has approved Tapentadol hydrochloride, according to a Nov. 24 press release.
Tapentadol hydrochloride is a centrally-acting synthetic analgesic, available as an immediate-release oral tablet in doses of 50 mg, 75 mg, or 100 mg.
Common side effects experienced by patients taking Tapentadol include nausea, dizziness, vomiting, and sleepiness. Tapentadol acts as an opioid (narcotic) and non-opioid, so physicians should also monitor patients who are taking Tapentadol for signs of abuse and addiction.